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Background & aims: The effect of lycopene-containing foods in prostate cancer development remains
undetermined. We tested whether a lycopene-rich tomato intervention could reduce the levels of
prostate speciﬁc antigen (PSA) in prostate cancer patients.
Methods: Prior to their curative treatment, 79 patients with prostate cancer were randomized to a
nutritional intervention with either 1) tomato products containing 30 mg lycopene per day; 2) tomato
products plus selenium, omega-3 fatty acids, soy isoﬂavones, grape/pomegranate juice, and green/black
tea (tomato-plus); or 3) control diet for 3 weeks.
Results: The main analysis, which included patients in all risk categories, did not reveal differences in
changes of PSA-values between the intervention and control groups. Post-hoc, exploratory analyses
within intermediate risk (n ¼ 41) patients based on tumor classiﬁcation and Gleason score post-surgery,
revealed that median PSA decreased signiﬁcantly in the tomato group as compared to controls (2.9%
and þ6.5% respectively, p ¼ 0.016). In separate post-hoc analyses, we observed that median PSA-values
decreased by 1% in patients with the highest increases in plasma lycopene, selenium and C20:5 n-3 fatty
acid, compared to an 8.5% increase in the patients with the lowest increase in lycopene, selenium and
C20:5 n-3 fatty acid (p ¼ 0.003). Also, PSA decreased in patients with the highest increase in lycopene
alone (p ¼ 0.009).
Conclusions: Three week nutritional interventions with tomato-products alone or in combination with
selenium and n-3 fatty acids lower PSA in patients with non-metastatic prostate cancer. Our observation
suggests that the effect may depend on both aggressiveness of the disease and the blood levels of
lycopene, selenium and omega-3 fatty acids.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).FAME, Fatty acid methyl ester; FFQ, Food Frequency Questionnaire; HPLC, High Performance Liquid Chromatography;
try; PUFA, poly-unsaturated fatty acids; PSA, prostate speciﬁc antigen; RCT, randomized controlled trial; SHBG, sex
lymorphism; WCRF, World Cancer Research Fund.
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Prostate cancer is the second most common cancer in men in
the world with nearly 900 000 new cases diagnosed each year [1].
The incidence and mortality of prostate cancer show large
geographical differences [2]. The epidemiological patterns suggest
that lifestyle and dietary factors impact the occurrence of prostate
cancer. Tomatoes have been identiﬁed as one possible candidate for
reducing the risk of prostate cancer with lycopene as the major
potential active component [3]. While the Second Expert Report by
the World Cancer Research Fund (WCRF) [4] concluded that lyco-
pene containing foods (mainly tomatoes) probably protect against
prostate cancer, the recently released Continuous Update Project
Report from WCRF states that no conclusion was possible due to
limited evidence [5].
Prostate speciﬁc antigen (PSA) is an important biomarker used
in clinical risk assessments, follow-ups and as part of risk stratiﬁ-
cation of prostate cancers patients [6,7]. The effect of tomatoes or
lycopene-containing foods on PSA values in patients with estab-
lished prostate cancer has not been well documented. In an un-
controlled trial, a tomato sauce intervention for 3 weeks reduced
PSA in a subgroup of prostate cancer patients [8], while lycopene
supplements or extracts seemed to be less effective in reducing PSA
[9e11]. However, the lycopene contents of tomato-based foods, as
well as lycopene bioavailability varies considerably [12] and may
impact the efﬁcacy of tomato-based interventions.
Several other foods or food components have also been sug-
gested to protect against prostate cancers [5]. The WCRF concludes
that there is still limited evidence for the association between
prostate cancer and these dietary components. Thus a second
intervention arm with selenium, omega-3 fatty acids, soy iso-
ﬂavones, grapes, pomegranates, tea and tomato-products was
included in our study to investigate possible additive effects on PSA.
The present 3-arm randomized controlled trial (RCT), aimed to
test whether a tomato based lycopene-rich diet changed the ki-
netics of PSA in patients with non-metastatic prostate cancer dur-
ing the three weeks period preceding the patients' curative
treatment. Furthermore, we performed two sets of exploratory
post-hoc analyses. First, we hypothesized that a lycopene-rich diet
during this period leads to a more favorable PSA proﬁle in inter-
mediate risk patients as compared to a matched control group.
Secondly, we tested whether the effects on PSA depend on
bioavailability of the active treatment components.
2. Subjects and methods
2.1. Ethics statement
This study was approved by the regional ethics committee in
Norway (REK Sør, no. S-06187). The study is registered in Clinical-
Trials.gov with no. NCT00433797. All participants signed a letter of
informed consent.
2.2. Subjects and study design
Subjects for this parallel group RCT were recruited from two
clinical centers within the Oslo University Hospital, Oslo, Norway;
the Norwegian Radium Hospital and Aker University Hospital be-
tween June of 2007 and March of 2012. Patients diagnosed with
non-metastatic prostate cancer (N0 and M0 as conﬁrmed by
negative chest X-ray, bone scintigraphy and pelvic MRI or CT), and
scheduled for either radical prostatectomy or high-dose radio-
therapy consisting of a combination of high-dose rate brachyther-
apy and pelvic external beam radiotherapy [13] were considered
eligible. Patients were invited to participate in the study by theirPlease cite this article in press as: Paur I, et al., Tomato-based randomize
Nutrition (2016), http://dx.doi.org/10.1016/j.clnu.2016.06.014counseling urologists, oncologist or study nurses. Exclusion
criteria: White blood cells outside normal reference window;
Hb < 11 g/dL; prior endocrine treatment; <5 year life-expectancy;
ECOG score >1; incontinence/urinary retention; critical comor-
bidity (e.g. cardiovascular disease, chronic obstructive pulmonary
disease, insulin dependent diabetes mellitus, vasculitis, inﬂamma-
tory bowel syndrome or other conditions which could inﬂuence
radiation therapy).
The risk classiﬁcation of the prostate cancer patients includes
PSA, pT-staging and Gleason score. Patients with low or interme-
diate risk according the D'Amico risk classiﬁcation [14] were
considered eligible for the study. In addition, 13 patients with
Gleason score 8 and 9, pT3a-stage or PSA 20 mg/L (provided that
they fulﬁlled all other inclusion and exclusion criteria) were also
considered eligible after individual evaluation by their oncologist/
urologist.
After surgery, the prostatectomy specimens enable new and
more precise tumor description [15]. Taking into account this post-
surgery information, we deﬁned an adjusted/alternative risk clas-
siﬁcation for prostatectomized patients in part following the 2013
European guidelines [16]. This adjusted risk classiﬁcation was
based on pT category and the Gleason score in the prostatectomy
specimen and included the pre-intervention PSA. Three risk groups
emerged among the study group: Low risk (pT1c-pT2a, and
PSA < 10 mg/L, and, Gleason score  6); Intermediate risk (pT2b-
pT2c, and/or 10 mg/L  PSA <20 mg/L, and/or Gleason score 7); or
High risk (pT3, and/or  PSA 20 mg/L, and/or Gleason score 8e10).
2.3. Randomization and blinding
At inclusion, patients were randomized to one of three arms; a
control group, a tomato group, and a tomato-plus group.
Randomization was computer generated real-time by the
“Department of Clinical Research Support” at the Oslo University
Hospital at time of inclusion. By assigning single digit numbers to
the interventions, randomization was blinded for the investigators
until after initial statistical analyses were performed.
2.4. Blood samples and handling
All blood samples were collected at the hospitals during routine
clinical visits. Blood samples were drawn by venipuncture before
the start of the diet-intervention, and at the end of the diet-
intervention (i.e. shortly before surgery/radiotherapy). For plasma
samples, blood samples (standard heparin, EDTA and citrate tubes)
were centrifuged (1500g for 10 min) at 4 C. Red blood cells were
collected from centrifuged citrate blood samples after the collec-
tion of citrate plasma and removal of the buffy coat. All samples
were stored at 70 C until analysis.
2.5. Interventions
The tomato intervention included tomato products with a
content of 30 mg lycopene per day (see Supplementary Table 1 for
details). In addition to the same amount of tomato products, the
tomato-plus intervention also included green tea (a cup made from
1 sachet) and black tea (a cup made from 1 sachet), pomegranate-
and grape juice (330 mL of each), 200 mg soy isoﬂavones, 200 mg 1-
selenomethionin and 3.13 g n-3 fatty acids per day (for details and
producers see Supplementary Table 2). The patients in the control
group were encouraged to continue their habitual diet.
In order to select tomato products to be included in the study,
we measured lycopene contents (experimental procedure below)
in 170 tomato products commercially available in Norway
(Supplementary Table 3). This screening revealed large differencesd controlled trial in prostate cancer patients: Effect on PSA, Clinical
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ucts. Six products were selected for the study based on their high
contents of lycopene per portion size (Supplementary Table 1).
Participants were provided with tomato products for 25 days and
were free to choose which of these products to consume, however
the total dose was adjusted to give ~30 mg of lycopene per day.
Self-reported compliance to the two interventions was regis-
tered by the participants in provided compliance questionnaire. In
both interventions combined, 85% of the patients completed all 21
days of their respective interventions, and the median (range) of
intervention days were 21.5 (12.0, 24.0) for the tomato group, and
22.0 (20.0, 24.0) for the tomato-plus group. One patient in the to-
mato group completed only 12 days of intervention due to surgery
on day 13. Otherwise all patients completed at least 18 days of
intervention.
One patient in the tomato-plus group discontinued the intake of
ﬁsh oil supplement only, due to regurgitation. No other side effects
were reported.2.6. Food and nutrient intakes
A validated food frequency questionnaire was used to assess
habitual food and nutrient intakes prior to the intervention [17,18].
There were no differences in the intakes of energy, tomatoes, tea,
grapes, pomegranate, tofu (soy), selenium, cod liver oil, omega-3-
or other dietary supplements between the intervention groups
(data not shown).2.7. Lycopene in tomatoes and tomato products
All products were purchased from large grocery stores in the
Oslo and Akershus area in Norway. When possible, at least three
samples per product were purchased from three different stores. All
products were stored as recommended by the producer. The con-
tents of lycopene in the tomatoes and tomato products was
measured using High Performance Liquid Chromatography (HPLC)
as described in [19].3. Clinical biochemical measurements
3.1. Prostate speciﬁc antigen
Levels of total PSA in heparin plasmaweremeasured at the Dept.
of Medical Biochemistry, Oslo University Hospital using the DELFIA
PSA Free/Total kit on the AutoDELFIA automatic immunoassay
system (Perkin Elmer, Boston, MA, USA). Samples were thawed and
mixed, and analyzed in duplicates. Tominimize analytical variation,
all samples in the study were analyzed in one run. Three serum
controls with PSA concentrations of 0.17, 3.8 and 18.1 mg/L (CV% of
7.8, 3.5 and 3.7, respectively) were analyzed at the start and end of
every plate.3.2. Carotenoids
Plasma carotenoids were detected using HPLC by Vitas (Oslo,
Norway). In dark-colored vials, proteins were precipitated from
25 mL plasma and carotenoids extracted with isopropanol added
internal standard (b-Apo-8-carotenal). The sample was mixed
thoroughly, and thereafter centrifuged. Subsequently, an aliquot of
the isopropanol phase was injected into an 1100-series HPLC with a
1260 diode array detector (453 nm) (Agilent Technologies, Palo
Alto, CA). Separation was performed on a 3 mm column (YMC C30
(150 mm  4.6 mm i.d.)) (YMC, Japan).Please cite this article in press as: Paur I, et al., Tomato-based randomize
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Polyunsaturated fatty acids in red blood cells were markers for
bioavailability and were measured by as Vitas (Oslo, Norway) using
gas chromatography with ﬂame ionization detector. Samples were
methylated with 3N MeOH HCl. Fatty acid methyl esters (FAMEs)
were extractedwith hexane, and samples were neutralized with 3N
KOH in water. After mixing and centrifuging the hexane phase was
injected into the gas chromatography with ﬂame ionization de-
tector. Analyses were performed on a 7890A GC with a split/split-
less injector, a 7683B automatic liquid sampler, and ﬂame
ionization detection (Agilent Technologies, Palo Alto, CA). Separa-
tions were performed on a SP-2380 (30m 0.25mm i.d. 0.25 mm
ﬁlm thickness) column from Supelco.
3.4. Selenium
Plasma selenium was measured by Fürst Medical Laboratory
(Oslo, Norway) using a PerkinElmer Sciex, Elan® DRC™ II (Shelton,
USA) Inductively Coupled Plasma Mass Spectrometry (ICP-MS) in-
strument was used. The 82Se isotope was measured in standard
mode. External calibrationwas used and the standard was matched
with sample-matrix by adding Selenium PerkinElmer Pure Atomic
Spectroscopy Calibration Standard, Matrix 2% HNO3, 1000 mg/mL
(Shelton, USA) to Autonorm™ (Billingstad, Norway). Samples,
standard and quality controls were diluted 1:20 with Milli-Q™ de-
ionized water (Millipore, Bedford, MA, USA) with 0.1% (vol:vol)
Nitric acid (65% m/v, Suprapur®, Merck, Darmstadt, Germany) and
0.5% (vol:vol) 1-Butanol (74.12 g/mol pro analysis, Merck, Darm-
stadt, Germany). 10 mg/L Rhodium PerkinElmer Pure Atomic Spec-
troscopy Calibration Standard, Matrix 10% HCl, 1000 mg/mL
(Shelton, USA) was added directly to the diluent and was used as an
internal standard.
3.5. Hormones
Routine biochemical measures of testosterone and sex
hormone-binding globulin (SHBG) were performed at the Depart-
ment of Medical Biochemistry, Oslo University Hospital.
3.6. Power calculation
Power calculation was performed based on an anticipated
change in mean PSA value in the tomato group or the tomato-plus
group. The estimated effect size was set to a 20% decrease from the
values in the control group. With a standard deviation of 3.5 mg/L, a
power of 0.8 and a signiﬁcance level of 0.05), an estimated 28
subjects in each group and 84 subjects in total, were needed. With
an estimated 70% rate of initial consent and 20% drop out rate, a
total of 160 patients were invited to take part in the study, of which
86 accepted and 79 completed the study (Fig. 1). The ﬁnal initial
consent rate was 54%, while the ﬁnal drop out rate was 8%.
3.7. Statistical analysis
Primary endpoints were changes in PSA. Secondary endpoints
were measures of plasma concentrations of carotenoids and sele-
nium and RBC concentrations of fatty acids. The number of samples
analyzed per endpoint differs slightly since some samples were not
available for analysis.
Pre-intervention values and PSA changes during the interven-
tion were not normally distributed and were thus tested statisti-
cally using Kruskal Wallis test and ManneWhitney test.
FishereFreemaneHalton test was used to identify statistical dif-
ferences in categorical data and contingency tables. For tests ofd controlled trial in prostate cancer patients: Effect on PSA, Clinical
Fig. 1. Study design and patient ﬂow.
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These statistical analyses were performed using IBM SPSS statistical
software version 20 (SPSS Inc., Chicago, IL, USA).
4. Results
In this RCT, 86 men with localized prostate cancer were allo-
cated to either tomato-, “tomato-plus-” or a control-group, and 79
subjects completed the trial (Fig. 1). Patient characteristics are
presented in Table 1.
The main analyses, which included all patients, did not reveal
differences in changes of PSA-values between the intervention and
control groups (Table 2).
Next, we proceeded with two sets of exploratory post-hoc an-
alyses. First we analyzed our data according to an alternative post-
surgery risk classiﬁcation (see Methods). As compared to the risk
classiﬁcation at the time of diagnosis, twenty four patients shiftedTable 1
Patient characteristics prior to the intervention.
Control (n ¼ 27
Median (range)
Age (y) a 64 (51, 74)
PSA (mg/L) a 9.3 (4.4, 55.0)
Treatment (Surgery/Radiotherapy) b 22/5
Pre-treatment risk classiﬁcation b (Low/Intermediate/High) 6/17/4
BMI (kg/m2) a 26.4 (22.4, 31.7
Testosterone (nmol/L) a 13.6 (4.2, 28.1)
SHBG (nmol/L) a 44 (25, 67)
Free testosterone index a ((testosterone/SHBG)*100) 33.2 (8.1, 49.3)
Gleason score (6/7/8/9)b (10/15/1/0)c
a KruskaleWallis tests was used to detect differences between groups.
b Counts are compared statistically using the FishereFreemaneHalton Test.
c One missing Gleason score prior to surgery.
Table 2
Baseline PSA values and changes during the intervention.
Control n ¼ 24
Median (range)
Tomato n ¼ 26
Median (range)
Baseline Change Baseline Change
PSA [mg/L] 9.34 (4.42, 55.0) 0.41 (8.53, 4.0) 8.54 (1.52, 25.90) 0.00 (3
a KruskaleWallis tests were used to detect differences between groups.
Please cite this article in press as: Paur I, et al., Tomato-based randomize
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risk due to changes in T-staging and/or Gleason score. Thus, of the
79 patients that completed the trial, 41 patients were reclassiﬁed as
intermediate risk, while 1 and 37 patients were reclassiﬁed as low
and high risk, respectively.
In those reclassiﬁed as intermediate risk patients based on our
post-surgery risk group classiﬁcation, the tomato based in-
terventions signiﬁcantly affected changes in PSA (p ¼ 0.041) during
the intervention (Table 3). Interestingly, median PSA decreased by
0.23 mg/mL in the tomato group as compared to a 0.45 mg/L increase
in the control group (p¼ 0.016) during the threeweek intervention.
Similar, however, non-signiﬁcant change was observed in tomato-
plus group (p ¼ 0.094). For both intervention groups combined
(n ¼ 27), PSA was not changed (median change: 0.0 mg/L) for pa-
tients with intermediate risk, which was signiﬁcantly different
from the expected increase in the control group (p ¼ 0.014 by
ManneWhitney Test).) Tomato (n ¼ 27)
Median (range)
Tomato-plus (n ¼ 25)
Median (range)
P-value
62.5 (48, 72) 64 (54, 75) 0.277
8.54 (1.5, 25.9) 10.6 (5.1, 31.5) 0.280
25/2 23/2 0.490
7/18/2 2/16/7 0.220
) 25.5 (18.4, 33.5) 26.4 (20.4, 48.2) 0.197
14.1 (6.6, 21.8) 13.4 (4.6, 34.4) 0.755
40 (19, 62) 38 (21, 106) 0.420
35.7 (21.1, 54.4) 32.4 (19.2, 65.2) 0.356
(13/13/0/1) (16/8/1/0) 0.252
Tomato-plus n ¼ 25
Median (range)
P-valuesa
Baseline Change Baseline Change
.30, 2.40) 10.60 (5.10, 31.50) 0.14 (12.40, 4.80) 0.280 0.416
d controlled trial in prostate cancer patients: Effect on PSA, Clinical
Table 3
Baseline PSA values and changes during intervention for post-surgery classiﬁed intermediate risk patients.
Control (n ¼ 13)
Median (range)
Tomato (n ¼ 17)
Median (range)
Tomato-plus (n ¼ 10)
Median (range)
P-valuesa
Baseline Change Baseline Change Baseline Change Baseline Change
PSA [mg/L] 6.91 (4.42,17.70) 0.45 (0.26, 2.24) 7.98 (1.52, 18.00) ¡0.23 (1.12, 1.90) 7.13 (5.10, 12.50) 0.28 (0.78, 1.20) 0.880 0.041b,c
Bold characters identify statistically signiﬁcant differences.
a KruskaleWallis tests were used to detect differences between groups.
b ManneWhitney Test p ¼ 0.016 for difference control vs tomato.
c ManneWhitney Test p ¼ 0.094 for difference control vs tomato-plus.
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tectomy specimens (n ¼ 37), no signiﬁcant differences in any PSA
measures were detected (data not shown).
The initial analyses between treatment groups did not take into
account the response to the intervention in terms of changes in
blood concentration for the intervention component (as a measure
of compliance and absorption). Self-reported compliance
(i.e. amount of products consumed) was 99% for the tomato inter-
vention and 96e99% for the tomato-plus group. Thus, as per pro-
tocol, the potential effects of variation in response to the
intervention were taken into account in the following post-hoc
analysis.
To test the response to the interventions, wemeasured lycopene
and selenium in plasma, and poly-unsaturated fatty acids (PUFAs)
in red blood cells. Overall, lycopene in plasma was more than
doubled in both intervention groups, and these changes were
signiﬁcantly different from controls for both interventions (tomato
p < 0.001, tomato-plus p < 0.001) (Table 4). Plasma selenium values
nearly doubled in the tomato-plus group during the intervention
period, whereas no changes were detected in either the control- or
the tomato-groups (p < 0.001 between the tomato-plus and the
control group) (Table 4). The fatty acid proﬁle of red blood cells
reﬂects the dietary intake of fatty acids [20]. The level of n-3 PUFAs
(C20:5 n-3, C22:5 n-3 and C22:6 n-3) all increased in the subjects in
the tomato-plus group, as compared to the controls (Table 4)
(p < 0.001 for all). A simultaneous decrease in several n-6 and n-9
fatty acids in the tomato-plus group (Table 4) conﬁrms bioavail-
ability of the supplement, and a shift in fatty acid proﬁle in the
tomato-plus subjects.Table 4
Biomarkers of the intervention.
Biomaker Control
Median (range)
Tomato
Median (range)
Baseline Change Baseline C
Carotenoid [mg/mL] control n ¼ 23, tomato n ¼ 26, tomato-plus n ¼ 25
Lutein 0.12 (0.04, 0.39) 0.01 (0.06, 0.14) 0.12 (0.04, 0.29) 0.
Zeaxanthin 0.03 (0.01, 0.14) 0.00 (0.05, 0.03) 0.03 (0.01, 0.05) 0.
b-kryptoxantin 0.06 (0.01, 0.18) 0.01 (0.04, 0.10) 0.05 (0.01, 0.21) 0.
a-carotene 0.05 (0.01, 0.24) 0.00 (0.09, 0.09) 0.03 (0.01, 0.10) 0.
b-carotene 0.18 (0.03, 0.50) 0.02 (0.18, 0.18) 0.14 (0.03, 0.30) 0.
Lycopene 0.32 (0.13, 0.62) 0.02 (0.15, 0.53) 0.24 (0.03, 0.68) 0.
Selenium [mmol/L] Control n ¼ 21, tomato n ¼ 24, tomato-plus n ¼ 23
Selenium 1.1 (0.8, 1.5) 0.0 (0.3, 0.2) 1.2 (0.8, 1.8) 0.
Fatty acid [% of total FAME weight] Control n ¼ 22, tomato n ¼ 24, tomato-plus n
C18:2 n-6 7.08 (5.31, 10.20) 0.26 (2.32, 9.78) 7.24 (4.63,12.35) 
C20:1 n-9 0.18 (0.12, 0.24) 0.00 (0.06, 0.03) 0.21 (0.16, 0.37) 
C20:3 n-6 0.79 (0.61, 1.29) 0.01 (0.21, 0.36) 0.88 (0.58, 2.02) 0.
C20:4 n-6 & 22:1 n-9 9.91 (7.88,13.22) 0.07 (3.14, 2.21) 9.74 (7.43,12.68) 0.
C20:5 n-3 1.41 (0.69, 2.15) 0.06 (0.26, 0.73) 1.49 (0.43, 2.49) 0.
C22:5 n-3 2.48 (1.83, 3.00) 0.03 (1.02, 1.06) 2.46 (1.21, 3.27) 0.
C22:6 n-3 6.10 (4.26, 7.84) 0.02 (2.10, 2.98) 6.02 (2.91, 8.08) 0.
Carotenoids in plasma were measured by HPLC. Selenium in plasma was measured by Ind
was measured as % of total Fatty acid methyl esters by Gas chromatography. Data is p
differences within the dataset, and the ManneWhitney test was used to compare group
a ManneWhitney Test p < 0.05 for difference control vs tomato.
b ManneWhitney Test p < 0.05 for difference control vs tomato-plus.
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between individuals, and thus we also investigated the individual
changes in lycopene, selenium and C20:5 n-3 (Fig. 2). For lyco-
pene, there was a strikingly wide variation in the increases in
plasma concentrations. Even though the self-reported compliance
to the intake of tomato-products was 99%, 3 subjects in the
tomato-group (Fig. 2E) and 1 subject in the tomato-plus group
(Fig. 2F) displayed marked decreases in plasma lycopene con-
centrations. Furthermore, 2 subjects in the control group dis-
played high increases in plasma lycopene, indicating increased
intake of tomatoes or lycopene supplementation during the
intervention period. In the tomato-plus group, all subjects
increased plasma selenium concentrations (Fig. 2C), while all but
one increased C20:5 n-3 (Fig. 2I). None of the subjects in the to-
mato- or control group had large increases in the plasma selenium
concentrations (Fig. 2B and A, respectively), while three subjects
in the tomato group and six subjects in the control group dis-
played marked increases in C20:5 n-3 (Fig. 2H and G).
Due to large variations in responses to the intervention, we
tested whether the PSA values were affected by individual changes
in lycopene, selenium and C20:5 n-3. Independent of the allocated
intervention group, we compared the PSA values for those patients
with an above median increase in lycopene, selenium or C20:5 n-3
as well as those patients with an above median increase in all three
biomarkers (Table 5). A statistically signiﬁcant decrease in PSA
(p ¼ 0.043) was found in those patients who had a more than
median increase in lycopene (n¼ 35), with no such decrease inmen
with a belowmedian change (n ¼ 35) (Table 5). The patients with a
high increase in lycopene, selenium and C20:5 n-3 combined, hadTomato-plus
Median (range)
P-value
hange Baseline Change Baseline Change
03 (0.12, 0.09) 0.14 (0.04, 0.24) 0.01 (0.06, 0.13) 0.498 0.272
00 (0.02, 0.02) 0.03 (0.02, 0.06) 0.01 (0.02, 0.02) 0.895 0.117
02 (0.17, 0.10) 0.06 (0.03, 0.21) 0.01 (0.04, 0.09) 0.345 0.088
00 (0.05, 0.09) 0.04 (0.01, 0.16) 0.00 (0.08, 0.04) 0.358 0.399
06 (0.16, 0.26) 0.13 (0.06, 0.59) 0.06 (0.18, 0.18) 0.762 0.157
25 (¡0.12, 0.68) 0.25 (0.09, 0.46) 0.32 (¡0.29, 0.75) 0.227 <0.001 a,b
0 (0.1, 0.2) 1.1 (0.9, 1.5) 0.9 (0.6, 1.3) 0.449 <0.001 a
¼ 24
0.11 (4.18, 1.43) 7.09 (5.05,13.71) ¡0.80 (¡7.82, 1.22) 0.605 0.023 b
0.00 (0.04, 0.03) 0.21 (0.14, 0.29) ¡0.01 (¡0.07, 0.02) 0.034 0.009 b
00 (0.11, 0.21) 0.86 (0.54, 1.61) ¡0.13 (¡0.57, 0.15) 0.287 <0.001 b
26 (0.60, 3.20) 10.15 (6.99,12.36) ¡0.41 (¡1.30, 2.64) 0.909 <0.001 b
02 (0.29, 0.40) 1.51 (0.70, 3.74) 0.98 (0.10, 1.72) 0.874 <0.001 b
03 (0.14, 0.90) 2.58 (1.36, 3.15) 0.34 (¡0.20, 1.04) 0.720 <0.001 b
14 (0.63, 1.91) 6.05 (3.51, 8.20) 0.49 (¡0.39, 2.15) 0.802 0.006 b
uctively Coupled Plasma Mass Spectrometry (ICP-MS). Fatty acids in red blood cells
resented as median (range). KruskaleWallis tests were used to identify statistical
s. Bold characters identify statistically signiﬁcant differences.
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Fig. 2. Individual changes for selenium, lycopene and C20:5 n-3. A-I) Individual change in biomarkers for each intervention group. Changes from before to after intervention for
each individual for A-C) selenium, D-F) lycopene, and G-I) C20:5 n-3 in red blood cells. Selenium in plasma was measured by Inductively Coupled Plasma Mass Spectrometry.
Lycopene in plasma was measured by HPLC. C20:5 n-3 in red blood cells was measured as % of total Fatty acid methyl esters (FAME) by Gas chromatography.
I. Paur et al. / Clinical Nutrition xxx (2016) 1e86an even more pronounced decrease in PSA (p¼ 0.006) compared to
those patients with below-median increases (Table 5).
Furthermore, changes in PSA during the intervention were
negatively correlated with the changes in lycopene (r ¼ 0.247,
p ¼ 0.034) for all patients included in the study. Additionally, post-
intervention PSA values were negatively correlated with the post-
intervention lycopene concentration (r ¼ 0.400, p ¼ 0.048).
5. Discussion
Since tomato intake may protect against prostate cancer, and
PSA is used in the clinical practice as a biomarker for prostate
cancer, we have tested whether tomato-based interventions may
dampen PSA increase in prostate cancer patients. In this RCT, 79
prostate cancer patients were treated with tomato products; a
combination of selenium, omega-3 fatty acids, soy isoﬂavones,
grape-and pomegranate juice, and green- and black tea in addition
to the tomato products; or control diet. The patients received the
diet intervention 3 weeks prior to prostatectomy or radiotherapy.
A crucial aspect of this food-based study is that we screened
tomato products for their lycopene content and selected only those
containing the highest levels of lycopene for use in the interven-
tion. Without this screening, we would most likely also have
included tomato products with low or intermediate lycopenePlease cite this article in press as: Paur I, et al., Tomato-based randomize
Nutrition (2016), http://dx.doi.org/10.1016/j.clnu.2016.06.014content. The very large variation in lycopene contents in the
products is noteworthy. It should also be noted that our screening is
performed in products available in Norway, and thus might not
completely reﬂect the lycopene content in products available in
other countries.
The main analysis, which includes all patients, revealed no dif-
ferences in PSA changes in intervention groups compared to the
control group. However, it is possible that the study ended up un-
derpowered for this primary analysis due to a lower than expected
initial consent rate.
Borel et al. [12] reported large variations in the bioavailability of
lycopene and such variations may help explain the wide variation
in lycopene changes in our intervention groups. We also ﬁnd large
variations in the C20:5 n-3 changes in red blood cells after PUFA
supplementation. Such variations in the response to omega-3
supplementation have also previously been reported [21], and we
speculate that these variations may be related to Single Nucleotide
Polymorphism (SNP)-related differences in fatty acid metabolism
[22]. When the individual variations of response to the in-
terventions were taken into account, we observed signiﬁcantly
lower PSA increases for patients with the highest plasma increases
in lycopene alone, and lycopene, selenium and C20:5 n-3 com-
bined. These data suggest that individuals with the highest increase
in plasma lycopene have a more favorable PSA development thand controlled trial in prostate cancer patients: Effect on PSA, Clinical
Table 5
PSA values compared between groups based on changes in lycopene, selenium and C20:5 n-3.
Low increase
Median (range)
High increase
Median (range)
P-valuea
Baseline Change Baseline Change Baseline Change
Changes in C20:5 n-3, selenium and lycopene (low increase n ¼ 17, high increase n ¼ 15) b
PSA [mg/L] 8.44 (5.48,18.90) 0.72 (1.63, 2.40) 9.03 (5.38, 30.20) ¡0.10 (¡12.40, 1.47) 0.407 0.006*
Changes in lycopene (low increase n ¼ 35, high increase n ¼ 35) b
PSA [mg/L] 9.74 (4.42, 31.50) 0.45 (3.30,4.80) 8.12 (1.52, 30.20) ¡0.02 (¡2.40, 1.70) 0.957 0.043*
Changes in C20:5 n-3 (low increase n ¼ 34, high increase n ¼ 33) b
PSA [mg/L] 8.28 (1.52, 25.90) 0.29 (8.53, 2.40) 9.72 (4.42, 31.50) 0.13 (12.40, 4.80) 0.144 0.178
Changes in selenium (low increase n ¼ 32 high increase n ¼ 27) b
PSA [mg/L] 9.00 (1.52, 19.60) 0.025 (8.53, 2.40) 11.20 (5.10, 31.50) 0.00 (12.40, 4.80) 0.100 0.411
a ManneWhitney test was used to compare groups.
b Groups are divided based on median change in plasma/red blood cell concentrations. Bold characters identify statistically signiﬁcant differences, * ¼ p < 0.05.
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analysis, subjects with intermediate risk prostate cancers in the
post-surgery risk reclassiﬁcation had signiﬁcant reduction in PSA in
the tomato group as compared to the control group. Even though
the changes in PSA in our post-hoc analyses are promising, our
study is possibly underpowered for these analyses, and thus further
RCTs are warranted in order to verify these ﬁndings.
Despite the widespread interest in the association between
prostate cancers and intake of tomatoes, randomized controlled
trials are limited both in number and quality, as also concluded by
the WCRF [5]. The effect of tomato products has only been tested in
one previous clinical trial in patients with established prostate
cancers. In an uncontrolled clinical trial, Chen et al. [8] found that a
3 week tomato sauce intervention (containing 30mg lycopene/day)
reduced PSA about 18% in 32 patients with intermediate-risk
prostate cancers.
RCTs with lycopene supplements (i.e. not tomato products)
have been inconclusive. A recent Cochrane review concluded with
no evidence of effect of lycopene on PSA, as only 3 RCT's were
found eligible to be included in the review, and two of these three
trials were viewed as being of high risk of bias [3]. In a RCT,
patients with metastatic prostate cancer undergoing orchidectomy
consumed 4 mg of lycopene daily [23]. For the patients consuming
lycopene, signiﬁcantly lower PSA values were seen after 2 years,
compared to surgical treatment alone. A Phase II RCT by Kucuk
et al. [24] treated patients with 30 mg of lycopene for a 3-week
intervention prior to prostatectomy. A non-signiﬁcant 18%
decrease of PSA was seen in the intervention group. In a non-
controlled clinical intervention trial Kumar et al. [9] explored the
effect of 15, 30, and 45 mg of lycopene daily (no control group) for
30 days prior to prostatectomy. They found no signiﬁcant differ-
ences in PSA-development within or between the groups. Another
uncontrolled trial in patients with castration resistant prostate
cancer showed no effect on PSA values by 30 mg of lycopene per
day for 3 months [10]. The lack of proper control groups, make
these results difﬁcult to interpret.
A recent Cochrane review found no effect of selenium on the risk
of prostate cancer [25]. Also, very few clinical trials have been
performed with n-3 PUFA, soy, grapes, pomegranate, green- or
black tea. In a recent RCT by Galet et al. [26], 4e6 weeks on a low fat
and high ﬁsh oil diet decreased cell cycle progression in prostate
cancer tissue, as compared to tissue from patients on a high fat diet.
Furthermore, in a RCT with genistein supplements for three week
prior to prostatectomy, a borderline signiﬁcant reduction in PSA as
compared to controls were observed [27]. Two clinical trials have
found increases in PSA doubling time in prostate cancer patients
with intake of pomegranate, however these results should be
interpreted with caution as both studies lack control arms [28,29].
In experimental models of prostate cancer, mice receivingPlease cite this article in press as: Paur I, et al., Tomato-based randomize
Nutrition (2016), http://dx.doi.org/10.1016/j.clnu.2016.06.014pomegranate extract displayed reduced tumor growth and lower
PSA levels, as compared to controls [30].
Two trials have previously been conducted with combined diet
interventions. However, these studies were performed either in
men at high risk of prostate cancer or in patients with biochemical
relapse. Fleshner et al. [31] found no effect of a combination of soy
(40 g), vitamin E (800 U), and selenium (200 mg) on progression
from high grade prostatic intraepithelial neoplasia to prostate
cancer in a placebo controlled trial. A combined supplement of
isoﬂavones, lycopene, silymarin, selenium, and several vitamins
and minerals reduced PSA slope in patients with rising PSA levels
after initial prostatectomy [32].
Our study suggests that daily consumption of lycopene-rich
tomato products may affect PSA values in prostate cancer patients
with intermediate risk proﬁles however this ﬁnding needs to be
conﬁrmed in RCTs. It is interesting to speculate that tomato-
products may delay the progression of intermediate risk prostate
cancer or keep indolent cancers in the highly differentiated stage.
Our observation may also be applicable to active surveillance pro-
tocols for prostate cancer patients, since PSA screening detects
many cases of prostate cancer who are referred to primary treat-
ment with potentially unnecessary morbidity. If our data can be
replicated in low risk cancer patients, lycopene-rich tomato prod-
ucts may be considered as part of an active surveillance in future
protocols.
In conclusion, this is the ﬁrst RCT where the effect of tomato-
products has been tested on PSA development in patients with
localized prostate cancers. Our ﬁndings support the importance of
controlling for changes in blood concentrations in dietary in-
terventions, as the largest reduction in PSA was detected in those
patients who had the highest increase in lycopene, selenium and
C20:5 n-3. Furthermore, our data suggest that daily consumption of
tomato products containing 30 mg lycopene for 3 weeks may
reduce PSAvalues in intermediate risk prostate cancer patients. The
indication of reduced PSA increase in intermediate risk prostate
cancer patients by tomato products warrants further investigation.
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